Please login to the form below

Olumiant

This page shows the latest Olumiant news and features for those working in and with pharma, biotech and healthcare.

Second TULIP trial resurrects AZ’s lupus drug anifrolumab

There are some encouraging signs with other drugs however, including mid-stage clinical results with Incyte/Eli Lilly’s Olumiant (baricitinib), Johnson &Johnson’s IL-12/IL-23 inhibitor Stelara (ustekinumab)

Latest news

AbbVie scores FDA approval for arthritis treatment upadacitinib

The JAK inhibitor market competition has also become increasingly saturated and upadacitinib will be taking on Pfizer’s Xeljanz and Eli Lilly’s Olumiant when it comes to market.
Gilead and Galapagos close in on filing for Xeljanz rival

If approved, filgotinib would likely be the fourth JAK inhibitor for RA after Pfizer’s $1.8bn seller Xeljanz (tofacitinib), Eli Lilly’s Olumiant (baricitinib), and AbbVie’s upadacitinib which has ... In both studies there was a low incidence of
New data keeps AbbVie’s star pipeline therapies on track

Lilly reported positive phase II results with its already-approved Olumiant (baricitinib) drug in the skin disorder at last year’s EADV, as did Pfizer with PF-04965842, a more selective
Gilead and Galapagos JAK contender scores in RA trial

Another player is Lilly’s Olumiant, though this is held back by safety concerns.
Gilead, Galapagos JAK inhibitor clears phase II test

DVT is a recognised side effect with Eli Lilly’s JAK1 inhibitor Olumiant (baricitinib), which finally made it to market for rheumatoid arthritis in Europe last year but was rejected in ... related. First-to-market JAK inhibitor Xeljanz (tofacitinib)

More from news
Approximately 5 fully matching, plus 19 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
Live webinar: Navigating new frontiers: Ways to find space in the future RA market

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.